Systemic Lupus Erythematosus is marked by altered immune regulation linked to waxing and waning clinical disease. Embodiments described herein identify sets of biomarkers/mediators and their use for informing and/or predicting a future SLE disease activity event such as an impending SLE flare or SLE-related organ inflammation. Such an approach can be beneficial in the management of lupus.

Provided are an anti-NGF antibody or an antigen-binding fragment thereof, a preparation method and an application thereof. Also provided is an isolated polynucleotide encoding the anti-NGF antibody or the antigen-binding fragment thereof, as well as a vector containing the isolated polynucleotide. Also provided is use of the antibody or the antigen-binding fragment thereof of the present invention in preparing the medicament for the treatment of NGF-mediated diseases or disorders.

Provided are a neutralizing antibody, which can specifically bind to NGF, or an antigen-binding fragment thereof, and a preparation method for producing the antibody. Further provided is an application of the antibody in the treatment of NGF-related diseases or disorders, especially in relieving or improving individual pain.

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

A method of treating and monitoring patient diagnosed with Autistic Spectrum disorder or Fragile X syndrome comprising measuring plasma biomarker levels of BDNF, sAPP, and sAPP alpha and adjusting the amount of a therapeutic compound according to the plasma levels of BDNF, sAPP and sAPPs. In one embodiment, the therapeutic compound is acamprosate.

The present invention relates to a sensor for the detection of Neurotrophic Factor (NF). The sensor, preferably a Screen Printed Electrochemical sensor (SPE), has a working electrode coated by a Molecularly Imprinted Polymer (MIP) imprinted by a NF. The invention also relates to a method for preparing such a sensor and comprising the steps of 1) formation of a cleavable linking layer on the working electrode of the sensor; 2) immobilization of NF molecules on the cleavable linking layer; 3) polymerization of m-PD on the working electrode of the sensor; and 4) cleavage of the cleavable linking layer thereby removing the NF molecules from the MIP layer.

An antibody or an antigen-binding fragment thereof is capable of specifically recognizing TrkA and uses thereof. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence having at least 95% identity with it: heavy chain variable region CDR sequences: SEQ ID NO: 1˜27, light chain variable region CDR sequences: SEQ IN NO: 28˜54. The above antibody can specifically targeted-bind to the TrkA receptor and block the binding of NGF to TrkA.

Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

The present invention relates to a sensor for the detection of Neurotrophic Factor (NF). The sensor, preferably a Screen Printed Electrochemical sensor (SPE), has a working electrode coated by a Molecularly Imprinted Polymer (MIP) imprinted by a NF. The invention also relates to a method for preparing such a sensor and comprising the steps of 1) formation of a cleavable linking layer on the working electrode of the sensor; 2) immobilization of NF molecules on the cleavable linking layer; 3) polymerization of m-PD on the working electrode of the sensor; and 4) cleavage of the cleavable linking layer thereby removing the NF molecules from the MIP layer.